Results 21 to 30 of about 1,770,471 (326)

Development of synthetic lethality in cancer: molecular and cellular classification

Signal Transduction and Targeted Therapy, 2020
Recently, genetically targeted cancer therapies have been a topic of great interest. Synthetic lethality provides a new approach for the treatment of mutated genes that were previously considered unable to be targeted in traditional genotype-targeted ...
Shijie Li, Win Topatana, Sarun Juengpanich   +2 more
exaly   +2 more sources

Genome‐scale gene/reaction essentiality and synthetic lethality analysis

Molecular Systems Biology, 2009
Synthetic lethals are to pairs of non‐essential genes whose simultaneous deletion prohibits growth. One can extend the concept of synthetic lethality by considering gene groups of increasing size where only the simultaneous elimination of all genes is ...
Patrick F Suthers, Alireza Zomorrodi, Costas D Maranas   +2 more
doaj   +2 more sources

Overview of Ferroptosis and Synthetic Lethality Strategies [PDF]

International Journal of Molecular Sciences, 2021
Ferroptosis, a term first proposed in 2012, is iron-dependent, non-apoptotic regulatory cell death induced by erastin. Ferroptosis was originally discovered during synthetic lethal screening for drugs sensitive to RAS mutant cells, and is closely related
Yuko Kinowaki, Towako Taguchi, Iichiroh Onishi, S. Kirimura, M. Kitagawa, Kouhei Yamamoto   +5 more
semanticscholar   +3 more sources

A metabolic synthetic lethality of phosphoinositide 3-kinase-driven cancer [PDF]

Nature Communications
The deregulated activation of the phosphoinositide 3-kinase (PI3K) pathway is a hallmark of aggressive tumors with metabolic plasticity, eliciting their adaptation to the microenvironment and resistance to chemotherapy. A significant gap lies between the
Guillaume P. Andrieu, Mathieu Simonin, Aurélie Cabannes-Hamy, Etienne Lengliné, Ambroise Marçais, Alexandre Théron, Grégoire Huré, Jérome Doss, Ivan Nemazanyy, Marie Émilie Dourthe, Nicolas Boissel, Hervé Dombret, Philippe Rousselot, Olivier Hermine, Vahid Asnafi   +14 more
doaj   +2 more sources

Research progress for the development of anti-tumor drugs based on synthetic lethality

生物医学转化, 2022
Synthetic lethality describes a phenomenon where mutation of any one of two non-lethal genes does not affect cell survival, whereas mutation of both genes significantly compromise cell viability.
Chen Pei, Mu Bo, Bin Huachao, Yang Shengyong   +3 more
doaj   +1 more source

Inhibiting PRMT5 induces DNA damage and increases anti-proliferative activity of Niraparib, a PARP inhibitor, in models of breast and ovarian cancer

BMC Cancer, 2023
Background Inhibitors of Poly (ADP-Ribose) Polymerases (PARP) provide clinical benefit to patients with breast and ovarian cancers, by compromising the DNA repair activity of cancer cells.
Shane O’Brien, Michael Butticello, Christine Thompson, Boris Wilson, Anastasia Wyce, Vivek Mahajan, Ryan Kruger, Helai Mohammad, Andy Fedoriw   +8 more
doaj   +1 more source

The role of protein interactions in mediating essentiality and synthetic lethality. [PDF]

PLoS ONE, 2013
Genes are characterized as essential if their knockout is associated with a lethal phenotype, and these "essential genes" play a central role in biological function.
David Talavera, David L Robertson, Simon C Lovell   +2 more
doaj   +1 more source

BRCAness, Homologous Recombination Deficiencies, and Synthetic Lethality.

Cancer Research, 2023
The concept of "BRCAness" was first described in 2004 to define the situation in which a homologous recombination repair (HRR) defect in a tumor relates to and phenocopies BRCA1 or BRCA2 loss-of-function mutations.
J. Murai, Y. Pommier
semanticscholar   +1 more source

Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance

Nature Communications, 2021
To identify approaches to target DNA repair vulnerabilities in cancer, we discovered nanomolar potent, selective, low molecular weight (MW), allosteric inhibitors of the polymerase function of DNA polymerase Polθ, including ART558.
D. Zatreanu, H. Robinson, Omar Alkhatib, M. Boursier, H. Finch, Lerin Geo, Diego Grande, V. Grinkevich, R. Heald, Sophie Langdon, Jayesh Majithiya, Claire L McWhirter, N. Martin, S. Moore, Joana Neves, E. Rajendra, M. Ranzani, Theresia A Schaedler, M. Stockley, Kimberley A. Wiggins, R. Brough, Sandhya Sridhar, Aditi Gulati, Nan Shao, Luned M. Badder, D. Novo, Eleanor G. Knight, Rebecca Marlow, S. Haider, E. Callen, Graeme Hewitt, J. Schimmel, R. Prevo, Christina Alli, A. Ferdinand, Cameron Bell, Peter Blencowe, C. Bot, M. Calder, Mark D Charles, J. Curry, Tennyson Ekwuru, Katherine E. Ewings, W. Krajewski, Ellen MacDonald, Hollie B. McCarron, Leon Pang, C. Pedder, L. Rigoreau, M. Swarbrick, E. Wheatley, Simon N. Willis, A. Wong, A. Nussenzweig, M. Tijsterman, A. Tutt, S. Boulton, G. Higgins, S. Pettitt, G. Smith, C. Lord   +60 more
semanticscholar   +1 more source

Modeling synthetic lethality [PDF]

Genome Biology, 2008
Abstract Background Synthetic lethality defines a genetic interaction where the combination of mutations in two or more genes leads to cell death. The implications of synthetic lethal screens have been discussed in the context of drug development as synthetic lethal pairs could be used to ...
Le Meur, Nolwenn, Gentleman, Robert
openaire   +2 more sources